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Abstract
Modern cancer therapy combines recombinant viruses with traditional chemotherapeutic agents 
that are metabolized by hepatic cytochrome P450 3A4 (CYP3A4). A single dose of recombinant 
adenovirus (Ad) expressing beta-galactosidase (AdlacZ) significantly alters CYP3A2, the 
correlate of CYP3A4, in rats for 14 days. Recombinant adenovirus expressing human p53 (Adp53) 
also suppresses CYP3A2. Plasma clearance of docetaxel (DTX) in animals given AdlacZ (3.38 ± 
0.22 L/h/kg) was significantly lower than that of those given DTX alone (6.41 ± 1.10 L/h/kg, 
p≤0.05). Area under the plasma concentration-time curve of DTX in rats given AdlacZ (2,987.37 
± 197.97 ng/ml/h) was significantly greater than those given drug alone (1,666.59 ± 317.04 
ng/ml/h, p≤0.05). Both viruses prolonged DTX half-life (t1/2). Ad infection may cause significant 
variability in the pharmacokinetics and pharmacodynamics of anti-cancer agents and should be 
considered when designing therapeutic regimens for patients with viral infection and those 
enrolled in clinical trials employing recombinant viruses.
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Recombinant adenoviruses have been shown to be the most efficient vectors for gene 
delivery due to their ability to infect both dividing and quiescent cells with high efficiency.1 
Adenovirus-based vectors are currently being developed as novel therapeutics for diverse 
applications including inherited genetic disorders, cancer, cardiovascular disease, 
neurodegenerative disorders and infectious disease.2 At present, cancer is the therapeutic 
target of most gene therapy clinical trials. One strategy of cancer gene therapy is the use of 
replication-deficient adenoviral vectors to transfer either immunostimulatory, anti-
angiogenic, suicide or tumor suppressor genes alone or in combination to reduce tumor 
growth and spread.3 To date, adenovirus-mediated delivery of the tumor suppressor gene, 
p53, (Adp53) has made the most progress in the clinic. One form of this construct has been 
marketed as Gendicine in China since 2004, while others are currently undergoing late-stage 
clinical trials for a variety of malignancies in several other countries.4 Studies in both 
preclinical models of disease and human clinical trials have shown that Adp53, when used in 
combination with traditional anti-cancer therapeutic agents, can significantly enhance drug 
potency.5-9 In light of this synergistic or additive effect, recombinant adenoviruses are, 
therefore, likely to be given in conjunction with chemotherapeutic agents.
Docetaxel (DTX) is one of the most potent antineoplastic agents with a broad spectrum of 
antitumor activity. It has been used to treat various malignancies including breast, lung, 
ovarian, head and neck, and prostate cancer. It exhibits cytotoxicity by stabilizing 
microtubules and preventing depolymerization to free tubulin.10 DTX is predominantly 
metabolized by hepatic cytochrome P450 3A4 (CYP3A4) and eliminated through biliary 
secretion. To date, four major metabolites of this drug have been identified that possess less 
cytotoxic activity with respect to the parent compound.11 Several preclinical studies have 
described improvement in response to DTX when used in combination with Adp53.7, 8 A 
marked pharmacological advantage of this approach has been highlighted in a phase II 
clinical trial where the use of DTX and doxorubicin in combination with ADVEXIN®, 
another adenovirus-p53 construct, has shown a greater reduction in tumor size compared to 
that seen with chemotherapy alone.9 Although several other reports have supported this 
finding, the mechanism by which this occurs is unknown.
CYP3A4 is predominantly found in the human liver and is involved in the metabolism and 
clearance of more than 50% of currently marketed drugs. Given its broad range of 
substrates, CYP3A4 plays a significant role in a large number of clinically relevant drug 
interactions.12 We have previously found that systemic administration of a first-generation 
adenovirus expressing E. coli beta-galactosidase (AdlacZ) alters expression and function of 
rat hepatic CYP3A2, an isoform homologous to human CYP3A4.13 Additional studies 
indicate that the biology of the transgene product can significantly influence changes in 
CYP3A2 noted during treatment with recombinant adenoviruses.14 Based upon these 
results, we developed the hypothesis that changes in rat hepatic CYP3A2 following systemic 
administration of adenovirus could alter the pharmacokinetic profile of other CYP3A2 
substrates given concomitantly either as part of a therapeutic regimen or for treatment of 
other underlying conditions. Therefore, the primary goal of this study was to determine how 
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systemic administration of recombinant adenoviruses influences the pharmacokinetics and 
tissue distribution of DTX, a CYP3A2 substrate, in a rat model.
Results
Effect of systemic administration of recombinant adenoviruses on hepatic CYP3A2 
expression and function prior to treatment with DTX
Rats were given a single dose (5.7 × 1011 vp/kg) of either Adp53 or AdlacZ through a 
catheter inserted in the jugular vein. AdlacZ, previously documented to suppress rat hepatic 
CYP3A213, was used as a positive control in these studies. Twenty-four hours after 
treatment with either virus, several animals from each group were sacrificed to characterize 
CYP activity and expression prior to DTX dosing. Remaining animals were given a single 
dose of DTX (10 mg/kg). Prior to DTX treatment, hepatic CYP3A2 catalytic activity was 
significantly reduced. The amount of 6β-hydroxytestosterone, the primary CYP3A2-specific 
metabolite of testosterone, generated in samples from animals treated with either virus was 
reduced by approximately 47% with respect to that found in samples from phosphate-
buffered saline (PBS) treated animals (Figure1a, p≤0.05). CYP3A1/2 protein was also 
reduced by AdlacZ and Adp53 (40% and 33%, respectively, Figure 1b). Real time RT-PCR 
revealed that virus-induced inhibition of CYP3A2 occurs at the transcriptional level. 
CYP3A2 mRNA levels were 60% and 49% of control for animals treated with AdlacZ and 
Adp53, respectively (Figure 1c, p≤0.05). Serum aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) levels were measured to assess liver toxicity. Both viruses 
significantly elevated serum AST, however, the most profound induction occurred in 
animals given AdlacZ. In this group, serum AST was four times above control values. A 
three-fold increase was seen in animals treated with Adp53 (Figure 1d, p≤0.01). A similar 
trend was observed in serum ALT (Figure 1e, p≤0.05).
Impact of systemic administration of recombinant adenoviruses on pharmacokinetics and 
tissue distribution of DTX
In order to determine how virus-induced changes in CYP3A2 affected the metabolism and 
clearance of DTX, pharmacokinetic parameters of the drug were measured 24 hours after 
virus administration. The presence of either virus markedly altered the pharmacokinetic 
profile of DTX (Figure 2a). The area under the plasma concentration time curve (AUC) for 
DTX was 2 and 1.4 fold greater in rats given AdlacZ and Adp53, respectively than that of 
animals receiving DTX alone (Table. 1). Administration of AdlacZ and Adp53 reduced 
DTX clearance by 47 % and 23 %, respectively. The terminal plasma half-life of DTX was 
prolonged 3 fold in the presence of either virus (Table 1, p≤0.05). Each virus significantly 
altered tissue distribution of DTX in the lung (Figure 2b). Samples from animals given 
AdlacZ contained about half the amount of drug found in tissue of animals given DTX 
alone. A similar result was seen with Adp53. There was no significant difference in the 
amount of DTX present in the liver and kidneys of animals treated with either virus and 
DTX or with the drug alone (Figure 2b, p=0.075).
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Effect of systemic administration of DTX on hepatic CYP3A2 expression and function 24 
hours following adenovirus infection
DTX itself can induce CYP3A4 gene expression in certain cell types such as peripheral 
mononuclear cells from those with lung cancer15 while leaving hepatic CYP3A4 
unaffected.16 Taking this into consideration, CYP3A2 expression and function was assessed 
after DTX administration in order to confirm our hypothesis that the synergistic effect 
between the drug and the adenovirus observed in the clinic was due to virus-induced 
changes in CYP. Twenty-four hours after administration of DTX, testosterone hydroxylation 
assays revealed no further changes in CYP3A2 activity with respect to saline treated 
animals. Hepatic CYP3A2 activity was still suppressed by approximately 35% in animals 
given either virus (Figure 3a). At this time, 48 hours after virus administration, hepatic 
CYP3A2 activity was still significantly compromised in animals receiving AdlacZ alone 
(p≤0.001) while it began to recover to baseline levels in animals given Adp53. DTX also did 
not affect CYP3A1/2 protein expression. Western blot analysis revealed that the significant 
reduction in CYP3A1/2 protein in animals treated with either virus alone remained at the 
same level when DTX was given (Figure 3b, p≤0.05). CYP3A2 mRNA was approximately 
50% of control in all treatment groups except AdlacZ treated animals (Figure 3c, p≤0.01). 
For this treatment group, CYP3A2 mRNA began to recover to 70% of that seen in samples 
from saline-treated rats.
Serum transaminase levels 24 hours following administration of DTX in the presence of 
recombinant adenovirus
Serum AST and ALT were measured to assess the degree of liver toxicity associated with 
systemic administration of DTX when given 24 hours after adenovirus. At this time point, 
48 hours after administration of virus, these enzymes were not significantly elevated above 
baseline values in animals treated with either virus alone. Despite this, serum AST was 
significantly elevated by a factor of 3 in all animals receiving DTX (Figure 4a, p≤0.01). 
ALT levels were unaffected by the drug (Figure 4b).
Effect of systemic administration of DTX on hepatic transgene expression and virus 
distribution
Hepatic tissue sections were stained histochemically to evaluate the degree of transgene 
expression after a single dose of AdlacZ. A dose of 5.7 × 1011 vp/kg transduced 
approximately 30% of hepatocytes 24 hours after administration (Figure 5a). There were no 
significant differences in the number of beta-galactosidase-positive cells present in the liver 
of animals treated with AdlacZ either in the presence or absence of DTX twenty-four hours 
later (Figures 5b and 5c). A quantitative ELISA confirmed that the amount of beta-
galactosidase in the liver of animals treated with AdlacZ alone (217 ± 57 ng beta-
galactosidase/mg protein) was similar to that of animals treated with AdlacZ and DTX (184 
± 70 ng beta-galactosidase /mg protein, Figure 5d). There was also no statistical difference 
in the amount of p53 mRNA in the liver, measured by RT-PCR, in samples from animals 
treated with Adp53 alone and in conjunction with DTX (Figure 5e). Together these results 
indicate that DTX does not alter transgene expression patterns when given 24 hours after the 
virus.
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There was also no statistical difference in the number of viral genomes in liver samples 
taken from animals given AdlacZ (4,253 ± 313 virus genomes(VG)/100 ng genomic DNA) 
and Adp53 (3,635 ± 573 VG/100 ng genomic DNA) alone (Figure 5f). The number of viral 
genomes present in the lung and the kidney of animals treated with AdlacZ were also 
approximately the same as those given Adp53 (Figures 5g and 5h). Pulmonary tissues of 
animals receiving AdlacZ and Adp53 contained 842 ± 175 and 774 ± 99 VG/100 ng 
genomic DNA respectively. Renal samples obtained from animals given AdlacZ contained 
291 ± 67 VG in 100 ng of renal genomic DNA. Those given Adp53 contained 218 ± 109 
VG/100 ng genomic DNA (Figure 5h). DTX did not significantly affect the distribution 
patterns of either virus. The number of viral genomes in the liver at this time were 3,676 ± 
316 (VG)/100 ng genomic DNA (AdlacZ) and 3,476 ± 514 (VG)/100 ng genomic DNA 
(AdlacZ + DTX, Figure 5f). Similarly, 3,301 ± 343 (VG)/100 ng genomic DNA and 3,423 ± 
756 VG/100 ng genomic DNA were found in hepatic isolates of animals receiving Adp53 
alone and with DTX respectively (Figure 5f). There were also no statistical differences in 
the number of viral genomes present in the lung or the kidney between any of the treatment 
groups (Figures 5g and 5h).
Discussion
The combination of virotherapy and chemotherapy has become a promising strategy for 
cancer treatment. Many reports have also illustrated that this combination affords superior 
clinical efficacy with respect to single-agent regimens for some cancers.17, 18 We have 
previously found that a single systemic dose of recombinant adenovirus significantly 
suppresses expression and function of hepatic CYP3A2 in the rat13, which is 90% 
structurally and functionally equivalent to human CYP3A4. Based on these results, if 
adenovirus is given to a patient in combination with other drugs primarily metabolized by 
this enzyme, it can promote and prolong the pharmacological actions of them by preventing 
their clearance and extending their time in the systemic circulation. However, most 
antineoplastic agents are potent, cytotoxic agents with very narrow therapeutic indices. 
Thus, increasing their plasma concentration could potentially cause serious adverse 
consequences.19
To further investigate potential changes in drug metabolism and distribution profiles during 
virus infection, we chose DTX, a CYP3A2 substrate used in combination with virotherapy, 
as a model drug. DTX was given 24 hours after adenovirus administration. This dosing 
regimen was selected based upon the fact that CYP3A2 would be significantly reduced13 
and to prevent compounded changes in CYP and the associated toxicity that might occur had 
the two agents been given simultaneously. Total CYP3A activity is a strong predictor of 
DTX clearance (CL) and is responsible for inter-patient variability of DTX metabolism.20, 
21 As shown in Table 1, treatment with either virus increased the AUC and reduced plasma 
CL. The half-life of DTX was also extended in animals given virus. Despite variable reports 
in the literature describing the effect of DTX on CYP15, 16, 22, results outlined in this 
report suggest that DTX alone does not affect hepatic CYP3A expression and function. 
Given this information, we believe that the observed changes in the pharmacokinetic profiles 
of DTX are largely due to virus-mediated inhibition of CYP3A2.
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Although intravenous administration, as performed in our studies, is not the most common 
method for delivering recombinant viruses for cancer and other clinical therapies utilizing 
these vectors; several studies have revealed that up to 90% of a single dose of adenovirus 
can disseminate to the liver within 10 minutes after localized, tissue-specific infusion.23, 24 
Thus, the improved efficacy of DTX when given with adenovirus in several clinical trials is 
still most likely due to virus-mediated changes in CYP in the liver and other target tissues. 
We also realize that although CYP enzymes responsible for drug metabolism and clearance 
are highly concentrated in the liver, local CYP expression patterns in other organs associated 
with drug metabolism and clearance such as the kidney and intestine25 as well as specific 
cancer cells also play a critical role in modulating the pharmacokinetic and 
pharmacodynamic profiles of anticancer agents.26-28 Thus, intratumoral infusion of 
recombinant adenovirus type 5 or administration of other viruses that are detargeted from 
the liver to reduce associated hepatotoxicity29, 30 may also alter local CYP expression 
patterns and dictate how certain cancers respond to a given therapeutic regimen. Studies to 
illustrate this effect in tumor cell lines and other organs associated with drug metabolism 
and clearance in preclinical models of cancer are currently underway in our laboratory.
It has been reported that DTX can change adenovirus transduction efficiency and transgene 
expression in vitro by altering virus transport patterns via microtubule networks.8, 31, 32 In 
contrast, we found no significant difference in transgene expression in the liver of animals 
receiving adenovirus alone or in combination with the drug. A similar result was seen with 
respect to the number of viral genomes distributed to target organs. One of the most 
surprising findings of this study was that recombinant adenoviruses alter tissue distribution 
of DTX in the lung but not other organs like the liver and kidney. The mechanism for this 
effect is not clear, however, virus-induced changes in tissue and plasma protein binding and 
blood flow may be responsible for this effect. An increase in plasma protein binding often 
correlates with a decrease in the free fraction of drug and reduces tissue penetration.33 
Many plasma components, including α1-acid glycoprotein (AAG), lipoproteins and albumin 
bind DTX with high affinity.10 In vitro studies have shown that DTX is extensively bound 
to AAG, an acute phase protein that is often elevated in response to inflammation.34 
Expression of this protein is stimulated by interleukin-1 (IL-1) and interleukin-6 (IL-6)35, 
cytokines commonly produced in response to systemic administration of recombinant 
adenoviruses in the rat36. Although, we did not assess AAG levels in this study, we believe 
that this phenomenon may have occurred in animals given the AdlacZ vector because a 
significant reduction in volume of distribution of DTX was found. This could also explain 
the greater changes in AUC and CL of DTX in animals given AdlacZ with respect to those 
given Adp53. We have previously found that recombinant adenovirus at the dose employed 
in these studies, suppresses several CYP isoforms responsible for the metabolism and 
clearance of compounds involved in regulation of renal blood flow.37 Imaoka et al. have 
recently reported that similar CYP isoforms such as CYP2B1, responsible for production of 
epoxyeicosatrienoic acids (EETs) and endothelium vasodilators, are present in the lung.38 It 
is possible that CYP2B1 may be suppressed during adenovirus infection, reducing 
pulmonary blood flow and limiting drug distribution to the lung. Additional studies to 
determine how systemic administration of recombinant adenovirus affects pulmonary 
CYP2B1 are warranted.
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The effect of microbial infection and inflammation on CYP expression and function has 
been extensively studied in vitro and in several animal models. Although the mechanism by 
which CYP is suppressed is not fully understood, cytokines and nitric oxide are thought to 
mediate this effect initially.39, 40 Along these lines, we have found that the immunogenic 
and biological nature of the transgene cassette can dictate virus-mediated changes in 
CYP3A2 for a period of 14 days14, beyond the timeframe associated with the acute phase of 
the innate immune response. In the present study, serum transaminases were markedly 
elevated by both viruses twenty-four hours after treatment (Figure 1), suggesting that 
adenovirus-mediated hepatotoxicity might initially contribute to repression of CYP3A2 
activity. However, CYP3A2 remained suppressed in all animals 48 hours after treatment 
despite the fact that serum ALT, a strong indicator of liver damage41, returned to baseline 
levels (Figure 4b) while AST, a strong indicator of toxicity in tissues other than the liver42 
was elevated in only those animals given DTX (Figure 4a). Thus, we believe that short lived 
inflammatory mediators may indeed play a role in adenovirus-induced changes in CYP 
expression and function, but other factors associated with certain cell signal transduction 
pathways initiated during infection in the liver may be responsible for long-term suppression 
of CYP.43 Additional studies to elucidate specific mechanisms by which adenovirus 
infection modulates CYP expression and function are currently under active investigation in 
our laboratories.
In summary, we have shown that a single systemic dose of recombinant adenovirus 
expressing the tumor suppressor gene, p53, significantly compromises hepatic CYP3A2 
expression and catalytic activity. This effect altered the pharmacokinetic profile of DTX, a 
CYP3A2 substrate and these results may be extrapolated to other drugs metabolized by this 
enzyme. The information described here is not only useful in the context that recombinant 
adenoviruses are currently used in the clinic for gene therapy and vaccine protocols but that 
this ubiquitous virus is capable of causing significant illness and high mortality in 
specialized patient populations. 44-46 Thus, it seems reasonable to conclude that care should 
be taken when designing therapeutic regimens that include drugs metabolized primarily by 
the CYP3A enzyme family for those treated with recombinant viruses and patients 
susceptible to adenovirus infection.
Methods
Adenovirus Vector Production
First-generation adenoviral vectors containing either wild-type p53 cDNA (Adp53) or E. 
coli beta-galactosidase (AdlacZ) under the control of a cytomegalovirus (CMV) promoter 
were amplified in human embryonic kidney (HEK) 293 cells and purified by two rounds of 
cesium chloride gradient ultracentrifugation. Virus concentration was calculated using the 
method of Maizel et al.47: virus particle/ml = (absorbance at 260 nm) × (dilution factor) × 
1.1 × 1012.
Administration of Adenoviral Vectors and DTX
All animal procedures were performed in accordance with the guidelines established by the 
National Institutes of Heath for humane treatment of animals and approved by the 
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Institutional Animal Care and Use Committee of The University of Texas at Austin. Adult 
male Sprague-Dawley rats (7 - 8 weeks old; Charles River Laboratories, Wilmington, MA) 
underwent jugular cannulation as previously described.48 Twenty four hours later, a single 
dose of 5.7 × 1011 vp/kg of either AdlacZ, Adp53 or PBS (vehicle) was administered in a 
volume of 500 μl followed by an equal volume of saline to ensure that virus was completely 
flushed from the catheter. Twenty-four hours after virus administration, 4-5 animals were 
sacrificed from each group to assess the effect of virus on CYP3A2. Remaining animals 
received 500 μl of either 10 mg/kg docetaxel (DTX, Sanofi-Aventis Pharmaceuticals, 
Bridgewater, NJ), docetaxel vehicle [13% ethanol, 25% polysorbate 80 (v/v), 62% saline 
(0.9%)] or PBS followed by 500 μl of saline through the jugular cannula. Blood was 
collected via the cannula immediately prior to docetaxel administration and at 5, 15, 30, 60, 
120, 240 and 480 min after dosing. Samples were processed and plasma collected by 
centrifugation at 3,000 × g for 10 minutes at 4°C and stored at -80°C for docetaxel analysis. 
Animals were sacrificed 24 hours after docetaxel administration. At this time, blood was 
collected and major organs (liver, lungs, kidneys) were harvested.
Testosterone Hydroxylation Assay
Hepatic microsomal proteins were prepared according to established methods.49 In order to 
assess hepatic CYP3A2 activity, samples were incubated with testosterone and formation of 
the enzyme specific metabolite, 6β-hydroxytestosterone, quantified by high-performance 
liquid chromatography as described.50
Western Blot analysis
Microsomal proteins (20 μg) and a CYP3A2 protein standard (XenoTech, LLC, Lenexa, KS) 
were separated by sodium dodecylsulfate polyacrylamide gel electrophoresis as described.13 
Immunoblotting for CYP3A2 protein expression was performed using a ployclonal rabbit 
anti-rat CYP3A2 antibody (1:3000 dilution, BD Gentest, Woburn, MA). CYP3A1 and 
CYP3A2 co-migrate during electrophoresis. The antibody used to detect CYP3A2 was 
polyclonal with cross reactivity to CYP3A1, therefore all protein levels for CYP3A2 are 
reported as CYP3A1/2.
Real-time RT-PCR
Hepatic RNA was isolated from tissue snap frozen in liquid nitrogen using TRIzol according 
to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). RNA was reversed 
transcribed with random nanomers using a RETROscript reverse transcription kit (Ambion, 
Austin, TX). Real-time PCR was carried out using the Power SYBR Green PCR Master Mix 
kit (Applied Biosystems, Foster City, CA) with the following primers specific for CYP3A2: 
5′-TTG ATC CGT TGT TCT TGT CA-3′ (forward) and 5′-GGC CAG GAA ATA CAA 
GAC AA-3′ (reverse). DNA amplifications were carried out using an ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, Foster City, CA) with the following 
cycling conditions: 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 seconds, and 62°C 
for 1 minute for a total of 40 cycles. Copy number was calculated from standard curves 
obtained using a cloned CYP3A2 template (plasmid DNA).
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Genomic DNA was extracted from frozen hepatic tissues using a QIAamp DNA mini kit 
(Qiagen Valencia, CA), according to the manufacturer’s instructions. Real-time PCR of 
adenovirus hexon protein was carried out according to an established method using the 
Taqman Universal PCR Master Mix kit (Applied Biosystems) and the following primers: 5′-
ACT ATA TGG ACA ACG ACG TCA ACC CAT T-3′ (forward) and 5′-ACC TTC TGA 
GGC ACC TGG ATG T-3′ (reverse).14 The internal probe sequence, tagged with 6FAM 
fluorescence dye at the 5′end and TAMRA quencher at the 3′ end, was 5′-ACC ACC GCA 
ATG CTG GCC TGC-3′.
Evaluation of Beta-Galactosidase Expression
The amount of beta-galactosidase in tissue samples was quantified by an enzyme-linked 
immunosorbent assay (ELISA, Roche Applied Science, Indianapolis, IN) and visually 
localized by histochemical staining as described previously.51
Evaluation of p53 Expression
The amount of p53 mRNA in hepatic tissue was assessed by a semi-quantitative RT-PCR 
method using the following primers: 5′-AAG CAG TCA CAG CAC ATG ACG GAG-3′ 
(forward) and 5′-GAG TCT TCC AGT GAG ATG ATG GT-3′ (reverse) as previously 
described.52 Values were normalized to 18S ribosomal mRNA.
Analysis of Serum Transaminases
Serum aspartate aminotransferase (AST) levels and alanine aminotransferase (ALT) levels 
were determined using VITROS AST/SGOT and ALT/SGPT DT slides on a VITROS DT60 
AutoAnalyzer (Ortho-Clinical Diagnostics).
Docetaxel Assay
Tissue samples were processed by a standard protein precipitation technique. DTX was 
isolated from these samples and plasma using a solid phase extraction technique as 
described.28 DTX concentrations were determined using a dual liquid chromatography-
mass spectrometry assay according to an established protocol.53
Pharmacokinetic Analysis
Pharmacokinetic parameters (plasma clearance (CL), the terminal elimination half life (t1/2), 
and the volume of distribution at steady state (Vss)) were calculated by a non-compartmental 
fit analysis using WinNonlin 4.0 (Pharsight Corporation, Mountain View, CA). The area 
under the plasma concentration-time curve (AUC) was calculated using the linear 
trapezoidal method with extrapolation of the terminal concentration to infinity.
Statistical Analysis
Statistical analysis of data was performed using SigmaStat (Systat Software, Inc., San Jose, 
CA). An unpaired two-tailed Student t test was used to compare differences in 
pharmacokinetic parameters, transgene expression and virus distribution. Differences in all 
other parameters were evaluated by a one-way analysis of variance (ANOVA) followed by a 
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Bonferroni/Dunn post-hoc test. For each of these tests, differences were determined to be 
significant when the probability of chance explaining the results was reduced to less than 
5% (p<0.05).
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Figure 1. Systemic administration of recombinant adenoviral vectors suppresses hepatic 
CYP3A2 24 hours after treatment
(a) In vitro catalytic activity of CYP3A2 microsomal proteins measured by the production of 
testosterone metabolite, 6β-hydroxytestosterone. (b) Western blot analysis of hepatic 
CYP3A1/2 protein expression. (c) mRNA levels of CYP3A2, as determined by real time 
RT-PCR. (d) Effect of systemic administration of adenovirus on serum aspartate 
aminotransferase (AST). (e) Effect of systemic administration of adenovirus on serum 
alanine aminotransferase (ALT). Results are reported as the mean ± the standard error (SE) 
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of the mean; n = 4-5 rats per treatment group. *P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001 with 
respect to vehicle control (PBS).
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Figure 2. Recombinant Adenoviruses Alter the Pharmacokinetic parameters of DTX
(a) Observed plasma concentration-time curve after intravenous administration of DTX (10 
mg/kg) to animals given the drug alone (DTX) and those treated with recombinant 
adenoviruses 24 hours earlier (AdlacZ + DTX, Adp53 + DTX). (b) Tissue distribution of 
DTX 24 hours after administration in the presence and absence of recombinant 
adenoviruses. Results are reported as the mean ± SE; n = 4-5 rats per treatment group. *** P 
≤ 0.001 with respect to vehicle control (PBS).
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Figure 3. DTX Does not Alter the Pattern of Virus-Induced Changes in Hepatic CYP3A2 
Expression and Function
(a) In vitro catalytic activity of CYP3A2 microsomal proteins measured 48 hours after 
administration of either adenovirus alone or in combination with DTX. (b) Western blot 
analysis of liver microsomal proteins for CYP3A1/2. (c) Gene expression of CYP3A2, as 
determined by real time RT-PCR. Results are reported as the mean ± SE; n = 4-5 rats per 
treatment group. *P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001 with respect to vehicle control (PBS).
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Figure 4. Systemic administration of DTX can increase serum transaminases 24 hours after 
treatment
Serum (a) AST and (b) ALT levels. Results are reported as the mean ± SE; n = 4-5 rats per 
treatment group. **P ≤ 0.01, *** P ≤ 0.001 with respect to vehicle control (PBS).
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Figure 5. DTX does not effect hepatic transgene expression and virus distribution
(a) Representative hepatic tissue section 24 hours after intravenous administration of 
AdlacZ. (b) Representative tissue section 48 hours after intravenous administration of the 
same virus. (c) Representative tissue section from an animal treated with AdlacZ and then 
DTX 24 hours later (sacrificed 48 hours after administration of virus). (d) Beta-
galactosidase expression, as measured by ELISA, in the liver 48 hours after administration 
of either AdlacZ alone or in combination with DTX. (e) p53 expression, as determined by 
RT-PCR. (f) Distribution of viral genomes in the liver following systemic administration of 
either adenovirus alone or in combination with DTX. (g) Distribution of virus in the lung 
after administration of either virus alone or in combination with DTX. (h) Distribution of 
viral genomes in the kidney following systemic administration of either adenovirus alone or 
in combination with DTX. Results are reported as the mean ± SE; n = 4-5 rats per treatment 
group.
Wonganan et al. Page 19

























Wonganan et al. Page 20
Table 1
Calculated Pharmacokinetic Parameters of DTX (10 mg/kg) Alone or in Combination 
with Recombinant Adenovirus (5 × 1011 vp/kg)a
Parameter DTX DTX + AdlacZ DTX + Adp53
AUC (ng/ml/h) 1,496.14 ± 281.62 2,987.37 ± 197.97* 2,113.44 ± 197.01
CL (L/h/kg) 7.35 ± 1.22 3.38 ± 0.22* 4.85 ± 0.43
Vss (L/kg) 17.43 ± 2.80 6.05 ± 0.67* 17.68 ± 2.54
t1/2 (h) 1.98 ± 0.10 5.06 ± 0.37* 5.55 ± 0.84*
AUC: area under plasma concentration-time curve extrapolated to infinity, CL: systemic clearance, Vss: volume of distribution at steady state, t1/2: 
terminal elimination half-life.
a
Data were obtained from plasma samples and reflect average values + standard errors of the means from 4-5 animals per treatment group.
*
p ≤ 0.05.
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